ANCOBON PRESCRIBING INFORMATION PDF

Package Insert-Flucytosine * Ancobon® is a The appropriate approved prescribing information should be consulted. Images. Group: antifungal. Capsule, mg [EDL] Solution for injection, g in ml [ EDL]. General information. Flucytosine is a fluorinated pyrimidine, non-antibiotic . Related Drug Information Flucytosine must be given with extreme caution to patients with bone marrow suppression. of America (IDSA) recommends 25 mg /kg/dose PO 4 times daily in combination with a lipid amphotericin B product.

Author: Gorisar Vizragore
Country: Comoros
Language: English (Spanish)
Genre: Life
Published (Last): 26 March 2011
Pages: 220
PDF File Size: 8.13 Mb
ePub File Size: 13.35 Mb
ISBN: 610-7-56432-557-3
Downloads: 73049
Price: Free* [*Free Regsitration Required]
Uploader: Vilrajas

Death from aplastic anaemia has been reported. Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Flucytosine. Hydroxychloroquine The risk or severity of adverse effects can be increased when Flucytosine is combined with Hydroxychloroquine.

The risk or severity of bleeding can be increased when Tesmilifene is combined with Infor,ation. Belinostat The risk or severity of adverse effects can be increased when Flucytosine is combined with Belinostat. Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Flucytosine. The risk or severity of bleeding can be increased when Idraparinux is combined with Flucytosine.

Flucytosine – Drugs Prescribing Information

The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Flucytosine. J02AX01 Flucytosine is a fluorinated pyrimidine derivative. Amphotericin B conventional or fluconazole is the preferred therapy. Flucytosine must be given with extreme prescribig to patients with bone marrow suppression.

Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Flucytosine. The therapeutic efficacy of Palifermin can be decreased when used in combination with Flucytosine.

predcribing Neonates The dose in neonates should be calculated in the same way as for adults and children, but the high possibility of renal impairment should be considered in this group either as intrinsic to their prescibing or as a result of other nephrotoxic therapies.

  HYDRODYNAMICS OF OFFSHORE STRUCTURES CHAKRABARTI PDF

Deoxyspergualin The risk or severity of adverse effects can be increased when Flucytosine is combined with Deoxyspergualin. Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Flucytosine. Cell membrane target Azoles lanosterol 14 alpha-demethylase inhibitors: The solution for injection should not be allowed to freeze as precipitation will occur.

The risk or severity of adverse effects can be increased when Trifluridine is combined with Flucytosine. Due to the potential for adverse events, the manufacturer recommends use of flucytosine during pregnancy only if the potential benefits outweigh the inflrmation risk to the fetus.

The risk or severity of adverse effects can be increased when Azacitidine is combined with Flucytosine.

Flucytosine

Meprednisone The risk or severity of adverse effects can be increased when Flucytosine is combined with Meprednisone. Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Flucytosine.

In the treatment of cryptococcal meningitis and severe systemic candidiasis it is recommended that Ancotil should be given in combination with amphotericin-B.

The risk or severity of adverse effects can be increased when Amphotericin B is combined with Flucytosine. Brentuximab vedotin The risk or severity of adverse effects can be increased when Flucytosine is combined with Brentuximab vedotin. Anthrax vaccine The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Flucytosine.

Ancotil 2.5g/250ml Solution for Infusion

The risk or severity of adverse effects can be increased when Flucytosine is combined with Bosutinib. The following initial dosage adjustments are based on the usual recommended dose in children of 25 to Hypericin The risk or severity of adverse effects can be increased when Flucytosine is combined with Hypericin.

However, it is still toxic for the normal human tissue. Amphotericin B Allylamines squalene epoxidase inhibitors: Site of disease – Potential opportunistic of disease. Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Flucytosine.

  FOSTEX FE208EZ PDF

However, candiduria may be the only microbiological documentation of disseminated candidiasis in high-risk patients anxobon. The risk or severity of adverse informmation can be increased when Flucytosine is combined with Hydrocortisone acetate.

Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Flucytosine. The risk or severity of adverse effects can be increased when Flucytosine is combined with Brentuximab vedotin.

Flucytosine may also be converted to fluorodeoxyuridylic acid, which inhibits the enzyme thymidylate synthase and disrupts DNA synthesis. The risk or severity of adverse effects can be increased when Levomefolic acid is combined with Flucytosine. Pralatrexate The risk or severity of adverse effects can be increased when Flucytosine is combined with Pralatrexate.

The therapeutic efficacy of Japanese encephalitis virus strain sa antigen formaldehyde inactivated can be decreased when used in combination with Flucytosine. Bosutinib The risk or severity of adverse effects can be increased when Flucytosine is combined with Bosutinib. Colchicine The risk or severity of adverse effects can be increased when Flucytosine is combined with Colchicine.

The risk or severity of bleeding can be increased when Flucytosine is combined with Ethyl biscoumacetate. Other mechanisms of flucytosine resistance include the up-regulated expression of a vacuolar glutathione S-conjugate pump that pumps flucytosine out of cells as well as the induced expression of a multi-drug resistance gene that permeates flucytosine out of cells. Monomethyl fumarate The risk or severity of adverse effects can be increased when Flucytosine is combined with Monomethyl fumarate.

Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Flucytosine. The risk or severity of adverse effects can be increased when Flucytosine is combined with Apremilast.

VPN